A phase Ib/II study of cancer stem cell inhibitor BBI608 administered with panitumumab in KRAS wild-type (wt) patients (pts) with metastatic colorectal cancer (mCRC) following progression on anti-EGFR therapy

被引：3
作者：
Ciombor, Kristen Keon
Edenfield, William Jeffery
Hubbard, Joleen Marie
O'Dwyer, Peter J.
Becerra, Carlos
Larson, Tim
Spira, Alexander I.
Grothey, Axel
Manoharan, Divya
Li, Wei
Li, Youzhi
Borodyansky, Laura
Li, Chiang
Bekaii-Saab, Tanios S.
机构：
[1] Ohio State Univ Wexner Med Ctr, Columbus, OH USA
[2] Univ Med Ctr, Greenville Hosp Syst, Inst Translat Oncol Res, Greenville, SC USA
[3] Mayo Clin, Rochester, MN USA
[4] Hosp Univ Penn, Philadelphia, PA 19104 USA
[5] US Oncol Res, TOPS Phase Program 1, Dallas, TX USA
[6] US Oncol Res, TOPS Phase Program 1, Minneapolis, MN USA
[7] US Oncol Res, Virginia Canc Specialists Res Inst, Fairfax, VA USA
[8] Boston Biomed Inc, Cambridge, MA USA
[9] Ohio State Univ Comprehens Canc Ctr, Columbus, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.3617
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3617
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
    Van Cutsem, Eric
    Eng, Cathy
    Nowara, Elzbieta
    Swieboda-Sadlej, Anna
    Tebbutt, Niall C.
    Mitchell, Edith
    Davidenko, Irina
    Stephenson, Joe
    Elez, Elena
    Prenen, Hans
    Deng, Hongjie
    Tang, Rui
    McCaffery, Ian
    Oliner, Kelly S.
    Chen, Lisa
    Gansert, Jennifer
    Loh, Elwyn
    Smethurst, Dominic
    Tabernero, Josep
    CLINICAL CANCER RESEARCH, 2014, 20 (16) : 4240 - 4250
  • [22] Phase II single-arm study of palbociclib and cetuximab rechallenge in KRAS/NRAS/BRAF wild-type (KRAS WT) metastatic colorectal cancer (mCRC) patients (pts)
    Sorah, Jonathan D.
    Moore, Dominic T.
    Reilley, Matthew
    Salem, Mohamed E.
    Sanoff, Hanna Kelly
    Triglianos, Tammy
    McRee, Autumn Jackson
    Lee, Michael Sangmin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [23] Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in KRAS Wild-Type Metastatic Colorectal Cancer
    Townsend, Amanda
    Tebbutt, Niall
    Karapetis, Christos
    Cooper, Pamela
    Singhal, Nimit
    Yeend, Susan
    Pirc, Louise
    Joshi, Rohit
    Hardingham, Jennifer
    Price, Timothy
    CLINICAL CANCER RESEARCH, 2018, 24 (16) : 3838 - 3844
  • [24] Panitumumab (Pmab) versus cetuximab (Cmab)/irinotecan (Iri) therapy among patients with KRAS wild-type (wt) metastatic colorectal cancer (MCRC).
    Kennecke, Hagen F.
    Chen, Leo
    Blanke, C. D.
    Cheung, Winson Y.
    Schaff, Kimberly
    Speers, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [25] A phase Ib/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT): Biomarker substudy.
    Townsend, Amanda Rose
    Hardingham, Jennifer
    Tebbutt, Niall C.
    Karapetis, Christos Stelios
    Singhal, Nimit
    Joshi, Rohit
    Yeend, Sue
    Cooper, Pamela
    Dorward, Hilary
    Price, Timothy Jay
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [26] A phase Ib/II study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer with KRAS wild type (WT).
    Townsend, A. R.
    Pirc, L.
    Hardingham, J.
    Karapetis, C. S.
    Tebbutt, N. C.
    Singhal, N.
    Price, T. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] A phase 1b study of the cancer stem cell inhibitor BBI608 administered with paclitaxel in patients with advanced malignancies
    Hitron, Matthew
    Stephenson, Joe
    Chi, Kim N.
    Edenfield, William Jeffery
    Leggett, David
    Li, Youzhi
    Li, Wei
    Gada, Keyur
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS
    Tomokazu Kishiki
    Hiroaki Ohnishi
    Tadahiko Masaki
    Kouki Ohtsuka
    Yasuo Ohkura
    Jyunji Furuse
    Takashi Watanabe
    Masanori Sugiyama
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 749 - 757
  • [29] Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS
    Kishiki, Tomokazu
    Ohnishi, Hiroaki
    Masaki, Tadahiko
    Ohtsuka, Kouki
    Ohkura, Yasuo
    Furuse, Jyunji
    Watanabe, Takashi
    Sugiyama, Masanori
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) : 749 - 757
  • [30] Panitumumab (pmab) plus AMG 102 in patients (pts) with wild-type KRAS metastatic colorectal cancer (mCRC): Updated safety results
    Eng, C.
    Tabernero, J.
    Nowara, E.
    Swieboda-Sadlej, A.
    Tebbutt, N. C.
    Mitchell, E. P.
    Davidenko, I.
    Chen, L.
    Smethurst, D.
    Van Cutsem, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345